Women's Health App 'Dayima' Secures RMB 130 Million in Funding Amid Theranos Scandal Over Exaggerated Blood-Testing Claims
Oct 22, 2015 08:05
CST Updated
08:05
1、Women's Health Management AppDa Yi Ma receives 1.3¥100 Million Financing
On October 21, the female health management app Dayima announced that it had secured a total of RMB 130 million in follow-on investments from Haitong Kaiyuan, By-Health, and its founder.
According to reports, Dayima is the mobile app with the largest global user base in the vertical category of women’s health. After more than three years of development, Dayima has established a closed-loop business model integrating tools, community, and e-commerce, earning recognition and favor from users, the industry, and investment institutions.
After securing two rounds of strategic equity investment this year, Dayima will partner with companies such as By-Health and Haitong Kaiyuan to accelerate its commercialization and capital development. Together, they will integrate and leverage mobile internet and other external resources, driving innovative growth in the women’s general health industry.
2、Collective HealthAcquired Google 8100$10,000 Investment
According to VCBeat, Collective Health, a U.S. corporate services company specializing in health insurance, secured $81 million in funding led by Google yesterday. Combined with the $38 million raised in March 2015, Collective Health has now raised a total of $119 million. The company stated that the latest round of financing will be used to build a health insurance management platform for B2B enterprises across China in 2016.
In the United States, 150 million people obtain health insurance through their employers. Collective Health, a California-based startup, believes that addressing the persistent issue of high healthcare costs must begin with corporate employers. Its solution eliminates insurance company intermediaries, enabling employers to create customized health insurance plans for their employees. In other words, it allows employers to offer more affordable, cloud-based, “à la carte” medical insurance benefits.
39. Pharmaceutical E-commerceMonthly Sales Ranking Announcement1Drug.com Takes the Crown
According to reports, Tmall Pharmacy’s sales volume surpassed RMB 600 million for the first time in September, representing a month-on-month increase of 13.53%. Medical devices accounted for 32%, over-the-counter (OTC) drugs for 26%, family planning products for 23%, contact lenses for 18%, and health supplements for 1%. Industry insiders revealed that this trend indicates consumers are increasingly inclined to make purchases online. Below is the comprehensive ranking of major pharmaceutical e-commerce platforms for September.
4, blood-testing company TheranosExposed for Exaggerating Its Technical CapabilitiesTriggering a Crisis of Trust
On October 15, U.S. time, The Wall Street Journal published an investigative report claiming that Theranos had grossly exaggerated its technological capabilities.
Theranos’s current market valuation has reached $9 billion, and it claims that its testing device, Edison, can detect 240 different biomarkers, such as high cholesterol and cancer, from just a few drops of blood. However, an investigation by The Wall Street Journal cited testimony from four anonymous former employees, revealing that Edison was capable of detecting only 15 biomarkers before December 2014.
Furthermore, the accuracy of Edison also appeared to be problematic. A Theranos employee accused the company of failing to report results that indicated issues with Edison’s precision, a practice that may have violated federal laboratory regulations. Additionally, it was reported that a significant portion of the company’s testing was conducted on conventional equipment purchased from companies such as Siemens, yet this information was consistently concealed.
In response to the revelations by The Wall Street Journal, Theranos denied the allegations and did not directly address the issues raised.
By John Wang
On October 21, the female health management app Dayima announced that it had secured a total of RMB 130 million in follow-on investments from Haitong Kaiyuan, By-Health, and its founder.
According to reports, Dayima is the mobile app with the largest global user base in the vertical category of women’s health. After more than three years of development, Dayima has established a closed-loop business model integrating tools, community, and e-commerce, earning recognition and favor from users, the industry, and investment institutions.
After securing two rounds of strategic equity investment this year, Dayima will partner with companies such as By-Health and Haitong Kaiyuan to accelerate its commercialization and capital development. Together, they will integrate and leverage mobile internet and other external resources, driving innovative growth in the women’s general health industry.
2、Collective HealthAcquired Google 8100$10,000 Investment
According to VCBeat, Collective Health, a U.S. corporate services company specializing in health insurance, secured $81 million in funding led by Google yesterday. Combined with the $38 million raised in March 2015, Collective Health has now raised a total of $119 million. The company stated that the latest round of financing will be used to build a health insurance management platform for B2B enterprises across China in 2016.
In the United States, 150 million people obtain health insurance through their employers. Collective Health, a California-based startup, believes that addressing the persistent issue of high healthcare costs must begin with corporate employers. Its solution eliminates insurance company intermediaries, enabling employers to create customized health insurance plans for their employees. In other words, it allows employers to offer more affordable, cloud-based, “à la carte” medical insurance benefits.
39. Pharmaceutical E-commerceMonthly Sales Ranking Announcement1Drug.com Takes the Crown
According to reports, Tmall Pharmacy’s sales volume surpassed RMB 600 million for the first time in September, representing a month-on-month increase of 13.53%. Medical devices accounted for 32%, over-the-counter (OTC) drugs for 26%, family planning products for 23%, contact lenses for 18%, and health supplements for 1%. Industry insiders revealed that this trend indicates consumers are increasingly inclined to make purchases online. Below is the comprehensive ranking of major pharmaceutical e-commerce platforms for September.
4, blood-testing company TheranosExposed for Exaggerating Its Technical CapabilitiesTriggering a Crisis of Trust
On October 15, U.S. time, The Wall Street Journal published an investigative report claiming that Theranos had grossly exaggerated its technological capabilities.
Theranos’s current market valuation has reached $9 billion, and it claims that its testing device, Edison, can detect 240 different biomarkers, such as high cholesterol and cancer, from just a few drops of blood. However, an investigation by The Wall Street Journal cited testimony from four anonymous former employees, revealing that Edison was capable of detecting only 15 biomarkers before December 2014.
Furthermore, the accuracy of Edison also appeared to be problematic. A Theranos employee accused the company of failing to report results that indicated issues with Edison’s precision, a practice that may have violated federal laboratory regulations. Additionally, it was reported that a significant portion of the company’s testing was conducted on conventional equipment purchased from companies such as Siemens, yet this information was consistently concealed.
In response to the revelations by The Wall Street Journal, Theranos denied the allegations and did not directly address the issues raised.
By John Wang